Reminder: You are viewing our sharing site. Content may differ from our live site.
Skip to main content

# Bleeding disorder - Whole blood and components

## Essential information

Includes

  Coagulation factor deficiencies:

  - Factor I (one) fibrinogen deficiency (afibrinogenaemia, hypofibrinogenaemia)
  - Factor II (two) prothrombin deficiency
  - Factor V (five) deficiency
  - Factor VII (seven) deficiency
  - Factor VIII (eight) deficiency (Haemophilia A)
  - Factor IX (nine) deficiency (Haemophilia B, Christmas Disease)
  - Factor X (ten) deficiency
  - Factor XI (eleven) deficiency
  - Factor XIII (thirteen) deficiency
  - Von Willebrand disease (types 1, 2 and 3)
Excludes

  Platelet disorders - see Platelet disorders
  Individuals who received coagulation factor concentrates (including prothrombin complex concentrates):

  - To treat and prevent the coagulopathy associated with trauma and/or massive transfusion
  - To reverse the effect of anticoagulants such as warfarin (see Transfusion)

### Scenarios

Affected individuals and carriers

Obligatory

  Must not donate if:

  1. Diagnosed with Haemophilia A (Factor VIII deficiency), Haemophilia B (Factor IX deficiency), Type 2 Von Willebrand Disease, Type 3 Von Willebrand Disease.
  2. The donor has received a transfusion since 1 January 1980.
  3. The donor has ever:
     1. Received coagulation factor concentrates, including blood derived and recombinant products, and/or
     2. Received or is currently on treatment to reduce or prevent excessive bleeding (e.g. desmopressin, tranexamic acid, oral contraceptive pill and similar hormone therapies).
  4. The donor has required or been advised they will require prophylactic treatment for surgery, dental treatment, or for any other procedure.
  5. There is a history of excessive bleeding or bruising.
  6. The donor is requiring monitoring and/or follow-up.
  7. There is associated organ involvement (e.g. liver damage).
  8. For acquired disorders, the underlying cause or treatment precludes donation (e.g. malignancy, monoclonal antibody therapy).
Discretionary

  If the donor has Type 1 Von Willebrand Disease and:

  1. Has not received a transfusion since 1 January 1980, and
  2. Has never received any type of coagulation factor treatment, and
  3. Has never received any other treatment to reduce or prevent excessive bleeding, and
  4. Has not received or been advised that they will require prophylactic treatment, and
  5. Has never had any excessive bleeding or bruising, and
  6. Is not requiring monitoring or follow-up, and
  7. The underlying cause and/or treatment does not preclude donation, accept.

  If the donor is a carrier of a coagulation factor deficiency, and:

  1. Has not received a transfusion since 1 January 1980, and
  2. Has never received any type of coagulation factor treatment, and
  3. Has never received any other treatment to reduce or prevent excessive bleeding, and
  4. Has not received or been advised that they will require prophylactic treatment, and
  5. Has never had any excessive bleeding or bruising, and
  6. Is not requiring monitoring or follow-up, accept.
See if relevant
  - Autoimmune disease
  - Ehlers-Danlos syndrome
  - Malignancy
  - Monoclonal antibody therapy and other biological modalities
  - Platelet disorders
  - Transfusion
Additional information

  Coagulation factor deficiencies can be inherited or can be acquired, associated with haematological, neoplastic, cardiovascular, liver or autoimmune disease.

  Some deficiencies cause significant bleeding, either spontaneously or in response to even minimal trauma or minor procedures. Individuals will have been assessed and advised about their condition and bleeding risk. They may have received treatment or been informed regarding the need for treatment in the future. The donor may have also been provided with a Bleeding Disorders Information Card.

  Some people with the carrier state (trait) may be at risk of bleeding (symptomatic carriers). The diagnosis of the milder forms or carrier status of coagulation factor deficiencies may arise from family screening, or through testing during investigation for menorrhagia (heavy periods), or bleeding during pregnancy or childbirth.

  If someone has had problems with bleeding or bruising, they may be at increased risk of complications from donation.

  The guidance contained in this entry is not intended for use for donors without a coagulation factor deficiency, for example for someone who may have taken tranexamic acid for heavy periods due to an underlying gynaecological cause.

  The current International Society on Thrombosis and Haemostasis (ISTH) classification recognises three types of Von Willebrand Disease: Type 1 is a partial quantitative deficiency of Von Willebrand Factor and is typically a milder form; the levels of von Willebrand Factor may overlap with the levels found in unaffected individuals.

  More severe effects are usually seen with Von Willebrand Disease types 2 and 3. Care should be taken to determine the type of Von Willebrand Disease, as only donors with type 1 are potentially eligible.

## Supporting information

Regulatory information

  Part of this entry is a requirement of the Blood Safety and Quality Regulations 2005.

Reason for change:
  Removal of section containing criteria for family members, carers and sexual partners of individuals treated with blood derived coagulation factor concentrates.
Version:
  Bleeding Disorder
Version details:

  WB-DSG Edition 203 Release 79 (17 February 2026)

BETA

This website recently launched. Help us improve it by giving your feedback (opens in new tab)